![]()
|
|
||||||||
J. Biol. Chem., Vol. 261, Issue 17, 7585-7587, 06, 1986
RR Ramsay and TP Singer
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an impurity in certain
batches of illicit heroin substitutes, is known to cause parkinsonian
symptoms and degeneration of the nigrostriatal cells in drug abusers and
primates. Neurotoxicity depends on oxidation of MPTP by monoamine oxidase
in brain cells to the dihydropyridinium form, which is further oxidized to
N-methyl-4-phenylpyridinium (MPP+), the 4- electron oxidation product. The
latter is widely believed to be the compound responsible for neuronal
destruction and the NADH dehydrogenase of the inner membrane has been
postulated to be its target. This enzyme is inhibited, however, only at
very high concentrations of MPP+, while the steady-state concentration of
MPP+ in the nigrostriatal cells of MPTP-treated animals is several orders
of magnitude lower. This paradox has now been resolved by the discovery of
an energized uptake system for MPP+ in mitochondria which rapidly
concentrates MPP+ to very high concentrations in the mitochondria at
micromolar external concentrations. The process is dependent on the
electrical gradient of the membrane, has a Km of about 5 mM, and is
completely blocked by respiratory inhibitors and uncouplers.
Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. M. Solano, M. J. Casarejos, J. Menendez-Cuervo, J. A. Rodriguez-Navarro, J. Garcia de Yebenes, and M. A. Mena Glial Dysfunction in Parkin Null Mice: Effects of Aging J. Neurosci., January 16, 2008; 28(3): 598 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Sredni, R. Geffen-Aricha, W. Duan, M. Albeck, F. Shalit, H. M. Lander, N. Kinor, O. Sagi, A. Albeck, S. Yosef, et al. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models FASEB J, June 1, 2007; 21(8): 1870 - 1883. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.C. Williams, L.S. Cartwright, and D.B. Ramsden Parkinson's disease: the first common neurological disease due to auto-intoxication? QJM, March 1, 2005; 98(3): 215 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakamura, V. P. Bindokas, J. D. Marks, D. A. Wright, D. M. Frim, R. J. Miller, and U. J. Kang The Selective Toxicity of 1-Methyl-4-phenylpyridinium to Dopaminergic Neurons: The Role of Mitochondrial Complex I and Reactive Oxygen Species Revisited Mol. Pharmacol., August 1, 2000; 58(2): 271 - 278. [Abstract] [Full Text] |
||||
![]() |
R. G. W. Staal, K. A. Hogan, C.-L. Liang, D. C. German, and P. K. Sonsalla In Vitro Studies of Striatal Vesicles Containing the Vesicular Monoamine Transporter (VMAT2): Rat versus Mouse Differences in Sequestration of 1-Methyl-4-phenylpyridinium J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 329 - 335. [Abstract] [Full Text] |
||||
![]() |
Y. Kitamura, T. Kosaka, J.-I. Kakimura, Y. Matsuoka, Y. Kohno, Y. Nomura, and T. Taniguchi Protective Effects of the Antiparkinsonian Drugs Talipexole and Pramipexole against 1-Methyl-4-phenylpyridinium-Induced Apoptotic Death in Human Neuroblastoma SH-SY5Y Cells Mol. Pharmacol., December 1, 1998; 54(6): 1046 - 1054. [Abstract] [Full Text] |
||||
![]() |
R. H. Moseley, L. J. Zugger, and R. W. Van Dyke The Neurotoxin 1-Methyl-4-phenylpyridinium Is a Substrate for the Canalicular Organic Cation/H+ Exchanger J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 34 - 40. [Abstract] [Full Text] |
||||
![]() |
P. Chan, D. A. Di Monte, J. W. Langston, and A. M. Janson (+)MK-801 Does Not Prevent MPTP-Induced Loss of Nigral Neurons in Mice J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 439 - 446. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |